Inspire Medical Systems, Inc. Announces Appointment of Bryan Phillips as General Counsel

Download as PDF

MINNEAPOLIS, MN – January 19, 2021 – Inspire Medical Systems, Inc. (NYSE: INSP)
(“Inspire”), a medical technology company focused on the development and
commercialization of innovative and minimally invasive solutions for patients with
obstructive sleep apnea (“OSA”), announced today the appointment of Bryan Phillips as
Senior Vice President, General Counsel, Chief Compliance Officer and Corporate
Secretary. Mr. Phillips is an accomplished legal executive with broad corporate
experience in the healthcare industry.

“We are beginning an exciting year at Inspire as we continue our growth trajectory,
despite the challenges of the pandemic during 2020, and are focused on further
expanding the adoption of our therapy and ensuring the organization is optimally
structured to support such advancements,” stated Tim Herbert, Inspire President and
CEO. “We look forward to leveraging Bryan’s extensive experience and expertise in
legal matters within the healthcare industry. He has a unique understanding of the
dynamics involved with a growing medical device company through his years at
Surmodics. Bryan is an important addition to our senior management team, and I am
excited to welcome him to the Inspire family.”

Most recently, Mr. Phillips served as Chief Legal Officer at Cerevel Therapeutics
Holdings, Inc., a publicly-traded clinical-stage biopharmaceutical company that
researches and develops therapies intended to treat central nervous system disorders.
Previously, he held various roles over a 14 year period at Surmodics, Inc., a publicly-
traded medical technology company, including Senior Vice President, Legal and Human
Resources, General Counsel and Secretary. Mr. Phillips has also served as patent
counsel at Guidant Corporation’s Cardiac Rhythm Management Group (now part of
Boston Scientific). He began his legal career at a Minneapolis-based intellectual
property law firm and earned a B.S. in mechanical engineering from the University of
Kansas and a J.D. from the University of Minnesota Law School.

“I am excited to join the team at Inspire at a time when the Company is growing at such
a robust rate,” said Mr. Phillips. “The development and commercialization of Inspire
therapy to date has been very impressive, and I look forward to contributing to Inspire’s
mission of serving the many patients with untreated OSA.”

About Inspire Medical Systems
Inspire is a medical technology company focused on the development and
commercialization of innovative and minimally invasive solutions for patients with
obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first and only FDA-
approved neurostimulation technology that provides a safe and effective treatment for
moderate to severe obstructive sleep apnea.

For additional information about Inspire, please visit

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. All statements other than statements of
historical facts are forward-looking statements, including, without limitation, statements
regarding the Company’s business, future growth and strategy. In some cases, you can
identify forward-looking statements by terms such as ‘‘may,’’ ‘‘will,’’ ‘‘should,’’ ‘‘expect,’’
‘‘plan,’’ ‘‘anticipate,’’ ‘‘could,’’ “future,” “outlook,” “guidance,” ‘‘intend,’’ ‘‘target,’’ ‘‘project,’’
‘‘contemplate,’’ ‘‘believe,’’ ‘‘estimate,’’ ‘‘predict,’’ ‘‘potential,’’ ‘‘continue,’’ or the negative
of these terms or other similar expressions, although not all forward-looking statements
contain these words.

These forward-looking statements are based on management’s current expectations
and involve known and unknown risks and uncertainties that may cause our actual
results, performance or achievements to be materially different from any future results,
performance or achievements expressed or implied by the forward-looking statements.
Important factors that could cause actual results, performance or achievements to differ
materially from those contemplated in this press release can be found under the
captions “Risk Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operations“ in our Annual Report on Form 10-K for the fiscal
year ended December 31, 2019, as updated in our Quarterly Report on Form 10-Q for
the quarter ended September 30, 2020, and as such factors may be updated from time
to time in our other filings with the SEC, which are accessible on the SEC’s website at and the Investors page of our website at These
and other important factors could cause actual results to differ materially from those
indicated by the forward-looking statements made in this press release. Any such
forward-looking statements represent management’s estimates as of the date of this
press release. While we may elect to update such forward- looking statements at some
point in the future, unless required by applicable law, we disclaim any obligation to do
so, even if subsequent events cause our views to change. Thus, one should not
assume that our silence over time means that actual events are bearing out as
expressed or implied in such forward-looking statements. These forward-looking
statements should not be relied upon as representing our views as of any date
subsequent to the date of this press release.

Investor and Media Contact:
Bob Yedid
LifeSci Advisors
[email protected]